10 Red Flags for Lucid in 2022 and Beyond
This growth stock is in for a challenging year.
Mindfully Curated
This growth stock is in for a challenging year.
The fields of genetics and genomics have been a cornerstone of our interest at ARK, and subjects we have explored in the past on the For You Innovation podcast. Today, analyst Simon Barnett dives a little deeper into this world, as we host Ivan Liachko…
Did you miss the big news?
An international trial exploring the effectiveness of tuberculosis (TB) treatment in children has led to a change in the World Health Organization’s global guidelines for managing the disease.
SND earnings call for the period ending December 31, 2021.
Shares of the online search specialist fell on a weak earnings report and news of a leadership change.